Proactiveinvestors recommends
Additional Information
Market: AMEX
Sector: Pharmaceuticals & Biotechnology
EPIC: RNN
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Rexahn Pharmaceuticals
www.rexahn.com

Rexahn’s goal is to be a world-class biopharmaceutical company developing and delivering novel cures for cancer and disorders of the central nervous system (CNS) to patients worldwide. Leveraging a powerful, multi-faceted discovery engine consisting of small signaling molecule discovery, computational modeling and nanotechnology-based drug targeting and delivery, we believe that we are well on our way to achieving our goal.

Full Rexahn Pharmaceuticals profile here
Is RNN a Buy, Sell or Hold?Get your FREE analysis of RNN
Pdf

Rexahn Pharma hires investment banker Frederick Frank as an independent consultant

8th Jun 2010, 9:39 am

Rexahn Pharmaceuticals Inc (AMEX:RNN) said it hired Frederick Frank, the current vice-chairman of Peter J. Solomon Co (PJSC), to advise on a range of corporate activities. As an independent consultant, Frank is expected to help Rexahn build its assets and drive shareholder value.

"Rexahn is in a great position with a strong pipeline, best-in-class products, and the positive Phase II clinical results of Serdaxin and Zoraxel. I am looking forward to helping the company build value for these assets," Frederick Frank said.

The company highlighted Frank’s extensive experience in investment banking, noted his specific experience in relation to the pharmaceutical, biotechnology, healthcare services, medical device and nutraceutical industries. “He has been involved in hundreds of financings, strategic alliances and merger and acquisition transactions in the global healthcare industry”, Rexahn stated.

Rexahn chairman and CEO Dr. Chang Ahn commented: “His expertise in global healthcare and 50 years of banking experience focused in biotechnology will be a great asset to the company.”

Rexahn is a clinical stage biopharmaceutical company, commercializing oncology and central nervous system (CNS) therapeutics. Rexahn’s core scientific expertise is in signal transduction; this has produced a drug portfolio with significant potential clinical value.

The company is working on a variety of therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs.

Rexahn currently has three drug candidates in Phase II clinical trials, Archexin, Serdaxin, and Zoraxel - all potential best in class therapeutics - and a pipeline of preclinical compounds in development to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms.

One of the company's most advanced development products is Serdaxin, which according to Rexahn prevents neuronal death which is a disease mechanism implicated in many brain disorders from depression to Parkinson’s and Alzheimer’s diseases. The treatment protects dopamine-releasing neurons from environmental damage. Serdaxin directly targets the disease mechanism by slowing or halting the progression of the disease, Rexahn state.

The company has multiple clinical programs planned for investigating Serdaxin in the treatment of anxiety disorders, Parkinson’s disease, Alzheimer’s disease and neurodegenerative illnesses, neuro-protection and bio-defense uses.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.